Objective To investigate the effects of simvastatin and salmeterol fluticasone propionate powder inhalation for chronic obstructive pulmonary disease (COPD) on pulmonary function.Methods All 200 cases of COPD were divided into control group (32 cases),simvastatin,inhalation group and combination group,3 groups of 56 patients each.Using quality of life assessment questionnaire (CAT) score,by monitoring of pulmonary function,blood gas analysis and C-reactive protein (CRP) changes,comparison of different treatment methods for 4 sets of COPD change of pulmonary function of patients with COPD.Results The simvastatin group,inhalation group,united group therapy for patients with scores of CAT score [(24 ±4),(24 ±4) and (19 ±3) scores],carbon dioxide partial pressure (PaCO2) [(50 ± 6),(50 ± 6) and (48 ± 6) mm Hg,CRP [(25 ± 9),(26 ± 9) and (18 ±6) mg/L] was significantly lower than that before treatment [CAT score:(27 ±5),(27 ±5) and (27 ±5)scores,PaCO2:(54±8),(54±7) and (54±6) mm Hg,CRP:(39±10),(39±10) and (39±10) mg/L],group differences were statistically significant (P ＜ 0.05).After treatment,the group of patients with CAT score,PaCO2,CRP were lower than those of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Simvastatin group,inhalation group,united group patients after forced vital capacity (FVC) [(2.3 ± 0.4),(2.3 ± 0.4) and (2.5 ± 0.5) L],forced expiratory volume in one second (FEV1) [(1.4 ± 0.4),(1.4 ± 0.4) L and (1.7 ± 0.5) L],forced expiratory second rate (FEV1/FVC) [(1.4 ± 0.4),(1.4 ± 0.4) and (1.7 ± 0.5) ％,PaO2 [(68 ± 8),(68 ± 8) and (72 ± 8) mm Hg] were higher than those before treatment [FVC:(2.1± 0.4),(2.1 ±0.4)Land (2.1±0.4) L,FEV1:(1.2±0.3),(1.2±0.3)L and (1.3±0.3) L,FEV1/FVC:(68 ±9),(66±9) and (67±9) ％,PaO2:(63 ±7),(64±8) and (64±8) mm Hg],group differences were statistically significant (P ＜0.05).After treatment,the group of patients with FVC,FEV1,FEV1/FVC,PaO2 higher than that of the simvastatin and inhalation group,the difference between groups was statistically significant (P ＜ 0.05).Conclusion Simvastatin combined with salmeterol fluticasone propionate powder for inhalation therapy can improve pulmonary function,blood gas analysis in patients with COPD.%目的 探讨辛伐他汀联合沙美特罗替卡松粉吸入剂对慢性阻塞性肺疾病(COPD)肺功能的影响.方法 选择临床确诊的COPD患者200例,根据治疗方法的不同分为对照组(32例)、辛伐他汀组、吸入剂组及联合组,后3组各56例.通过生活质量评估问卷(CAT)评分、测肺功能、血气分析指标和C反应蛋白(CRP)的动态改变,比较不同治疗方法对COPD患者肺功能的影响.结果 辛伐他汀组、吸入剂组、联合组患者治疗后CAT评分[(24±4)、(24±4)和(19±3)分]、PaCO2[(50±6)、(50±6)和(48±6)mm Hg(1 mm Hg=0.133 kPa)]、CRP[(25±9)、(26±9)和(18±6) mg/L]明显低于治疗前[CAT评分:(27±5)、(27±5)和(27±5)分,PaCO2:(54±8)、(54±7)和(546)mm Hg,CRP:(39±10)、(39±10)和(39±10) mg/L] (P ＜0.05).治疗后,联合组患者CAT评分、PaCO2、CRP均低于辛伐他汀组和吸入剂组(P＜0.05).辛伐他汀组、吸入剂组、联合组患者治疗后用力肺活量(FVC)[(2.3±0.4)、(2.3±0.4)和(2.5±0.5)L]、第1秒用力呼气容积(FEV1)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)L]、第1秒用力呼气容积占用力肺活量百分比(FEV1/FVC)[(1.4±0.4)、(1.4±0.4)和(1.7±0.5)％]、PaO2[(68±8)、(68±8)和(72±8)mm Hg]均较高于治疗前[FVC:(2.1±0.4)、(2.1 ±0.4)和(2.1±0.4)L,FEV1:(1.2±0.3)、(1.2±0.3)和(1.3±0.3)L,FEV1/FVC:(68±9)、(66±9)和(67±9)％,PaO2:(63 ±7)、(64±8)和(64±8)mm Hg](P＜0.05).治疗后,联合组患者FVC、FEV1、FEV1/FVC、PaO2高于辛伐他汀组和吸入剂组(P＜0.05).结论 辛伐他汀联合沙美特罗替卡松粉吸入剂治疗可改善COPD患者肺功能、血气分析指标,减轻呼吸困难.
展开▼
